Literature DB >> 12694813

The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats.

Torill Berg1.   

Abstract

The K+ channel inhibitor 4-aminopyridine induced an immediate increase in blood pressure and tension in spontaneously hypertensive rats (SHR). Further analysis strongly suggested this to be due to closure of vascular smooth muscle K+ channels, as previously concluded for normotensive rats (WKY). The tension response was greater in SHR than WKY, suggesting an increased channel activity in order to compensate for the high total peripheral vascular resistance in SHR. The response was enhanced after nitric oxide (NO) synthase inhibitor in both strains, probably reflecting increased channel activity after elimination of the NO-cGMP pathway. The response in SHR but not WKY was increased after alpha(1)-adrenoceptor inhibition and adrenalectomy but not sympathetic nerve transmitter depletion. It increased also after angiotensin AT(1) and endothelin ET(A) receptor antagonists and protein kinase C inhibitor. These results indicated an increased adrenal catecholamine, angiotensin AT(1) and endothelin ET(A) activation of the phospholipase C-protein kinase C pathway in SHR, inhibiting the 4-aminopyridine-sensitive K+ channels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694813     DOI: 10.1016/s0014-2999(03)01555-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 2.  Heart of the matter: coronary dysfunction in metabolic syndrome.

Authors:  Zachary C Berwick; Gregory M Dick; Johnathan D Tune
Journal:  J Mol Cell Cardiol       Date:  2011-07-13       Impact factor: 5.000

3.  Contribution of voltage-dependent K⁺ channels to metabolic control of coronary blood flow.

Authors:  Zachary C Berwick; Gregory M Dick; Steven P Moberly; Meredith C Kohr; Michael Sturek; Johnathan D Tune
Journal:  J Mol Cell Cardiol       Date:  2011-07-12       Impact factor: 5.000

4.  Identification and functional characterization of protein kinase A-catalyzed phosphorylation of potassium channel Kv1.2 at serine 449.

Authors:  Rosalyn P Johnson; Ahmed F El-Yazbi; Morgan F Hughes; David C Schriemer; Emma J Walsh; Michael P Walsh; William C Cole
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

5.  Plasma Norepinephrine in Hypertensive Rats Reflects α(2)-Adrenoceptor Release Control Only When Re-Uptake is Inhibited.

Authors:  Torill Berg; Sven Ivar Walaas; Bjørg Åse Roberg; Trang Thi Huynh; Jørgen Jensen
Journal:  Front Neurol       Date:  2012-11-08       Impact factor: 4.003

6.  Simultaneous parasympathetic and sympathetic activation reveals altered autonomic control of heart rate, vascular tension, and epinephrine release in anesthetized hypertensive rats.

Authors:  Torill Berg; Jørgen Jensen
Journal:  Front Neurol       Date:  2011-11-23       Impact factor: 4.003

7.  Altered β1-3-adrenoceptor influence on α2-adrenoceptor-mediated control of catecholamine release and vascular tension in hypertensive rats.

Authors:  Torill Berg
Journal:  Front Physiol       Date:  2015-04-20       Impact factor: 4.566

8.  Voltage-Sensitive K(+) Channels Inhibit Parasympathetic Ganglion Transmission and Vagal Control of Heart Rate in Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurol       Date:  2015-12-08       Impact factor: 4.003

9.  Angiotensin AT1 - α2C-Adrenoceptor Interaction Disturbs α2A-auto-Inhibition of Catecholamine Release in Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurol       Date:  2013-06-10       Impact factor: 4.003

10.  Tyramine Reveals Failing α2-Adrenoceptor Control of Catecholamine Release and Total Peripheral Vascular Resistance in Hypertensive Rats.

Authors:  Torill Berg; Jørgen Jensen
Journal:  Front Neurol       Date:  2013-02-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.